Fillmore Capital Partners (FCP), a San Francisco-based private investment firm, announced a $100 million capitalization for AlixaRx, spinning it off from Drumm Corp. This significant investment highlights FCP’s commitment to innovative healthcare solutions.
AlixaRx’s innovative pharmacy model, developed over four years within Drumm Corp., a holding company for FCP’s healthcare companies, addresses the evolving needs of the healthcare industry. FCP recognized the increasing demands on healthcare providers and government programs like Medicare and Medicaid, leading to the creation of AlixaRx’s automated and integrated pharmacy system.
“AlixaRx leverages the clinical and industry expertise within the FCP family of healthcare companies,” said Ron Silva, President and CEO of Fillmore Capital Partners. “We foresaw the need for a system that could serve diverse healthcare settings and providers, leading to the development of AlixaRx’s advanced pharmacy platform.”
Establishing AlixaRx as an independent entity with substantial capital allows for maximized growth potential and continued development of its cutting-edge technology. This strategic move by Fillmore Capital Partners positions AlixaRx for leadership in the rapidly expanding pharmacy automation sector.
AlixaRx’s full-service pharmacies employ clinical pharmacists and technicians who utilize automated dispensing technology, electronic medication cabinets, and sophisticated clinical software. This comprehensive approach ensures 24/7 access to critical medications, reduces costs for payers, and contributes to overall healthcare system savings.
In under two years, AlixaRx has created approximately 300 jobs. Fillmore Capital Partners anticipates significant growth for AlixaRx, projecting it to become a leader in pharmacy automation within the post-acute healthcare sector.
“Over 17,000 skilled nursing facilities could benefit from AlixaRx’s advanced system,” Silva added. “Fillmore Capital Partners’ vision for AlixaRx extends beyond post-acute care, with ongoing discussions to expand into other healthcare settings.” AlixaRx, headquartered in the Dallas Metroplex, is poised for significant expansion under the guidance and investment of Fillmore Capital Partners.
AlixaRx’s expansion strategy, supported by Fillmore Capital Partners, includes exploring opportunities beyond the post-acute sector. The company is actively engaging with various healthcare providers who recognize the value AlixaRx brings to patients and residents. This proactive approach reinforces Fillmore Capital Partners’ commitment to long-term growth and innovation in the healthcare industry.
Fillmore Capital Partners’ investment in AlixaRx underscores its dedication to developing and supporting companies that address critical needs within the healthcare sector. The spin-off and substantial capitalization will enable AlixaRx to further refine its technology and expand its reach, ultimately benefiting patients and the broader healthcare landscape. The strategic vision of Fillmore Capital Partners has positioned AlixaRx for continued success and innovation in the dynamic field of pharmacy automation.
